Alector Stock News

ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022

Alector Inc (NASDAQ: ALEC ) is flashing some AL001 (latozinemab) Phase 2 data at an Alzheimer’s and Parkinson’s disease conference, this time in dementia with a different type of mutation: C9orf72. Results in this cohort also showed elevated progranulin levels in both plasma and cerebrospinal fluid … Full story available on Benzinga.com

During the last session, Alector Inc. (NASDAQ:ALEC)’s traded shares were 0.59 million. At the end of the trading day, the stock’s price was $13.99, reflecting an intraday loss of -5.02% or -$0.74. The 52-week high for the ALEC share is $43.32, that puts it down -209.65 from that peak though still a striking 18.44% gain … After Alector Inc. (NASDAQ: ALEC) Surges -285.99% From Highs, What Will It Look Like? Read More »

SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ: ALEC ), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will present at the following upcoming investor conferences: Barclays Global Healthcare Conference (Miami, Florida) Wednesday, March 16, 2022 at 3:20 p.m. ET, Fireside Chat Stifel CNS Days (Virtual) Monday, March 28, 2022 at 11:30 a.m. ET, Corporate Presentation Live webcasts of each conference presentation will be available … Full story available on Benzinga.com

The shares of the clinical-stage biotech, Alector (ALEC) have reached a 15-month low after Stifel downgraded it to Hold from Buy with cautious remarks on the company’s dementia…

Gainers: Voyager Therapeutics VYGR +22%. 908 Devices (MASS) +16%. Viemed Healthcare VMD +10%

GlaxoSmithKline PLC found using ticker (GSK) have now 2 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 51.5 and 45.64 with a mean TP of 48.57. With the stocks previous close at 41.86 this now indicates there is a potential upside of 16.0%. The 50 day MA is 44.16 and the 200 day MA is 41.31. The company has a market capitalisation of $105,612m. You can visit the company''s website by visiting: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets=GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $122,541m based on the market concensus. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering the discovery and development of immuno-neurology therapeutics, today announced management will participate in a panel discussion at the Cowen Annual Health Care Conference on Tuesday, March 8, 2022, at 2:10 p.m. ET.

Alector (NASDAQ: ALEC ) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Alector missed estimated earnings by 257.89%, reporting an EPS of $-0.68 versus an estimate of $-0.19. Revenue … Full story available on Benzinga.com

Alector press release (ALEC): Q4 GAAP EPS of -$0.68 misses by $0.75.Revenue of $14M (+188.7% Y/Y) misses by $69.82M.

Alector (ALEC) appoints Marc Grasso, M.D.,as CFO and will play a critical role in supporting corporate strategy. He will report to Arnon Rosenthal, Ph.D., CEO and brings

Zacks Investment Research cut shares of Alector from a hold rating to a strong sell rating in a report published on Thursday, Zacks.com reports. According to Zacks, Alector

Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa

Biotech companies have seen an economic boom lately thanks to the COVID-19 Pandemic and the need for effective treatments. Alector has benefited from the same positive trend in financials despite bein

Alector develops innovative therapeutic approaches for treating neurodegeneration. It is a critical stage biotechnology company.